| Literature DB >> 7570001 |
R M Blaese1, K W Culver, A D Miller, C S Carter, T Fleisher, M Clerici, G Shearer, L Chang, Y Chiang, P Tolstoshev, J J Greenblatt, S A Rosenberg, H Klein, M Berger, C A Mullen, W J Ramsey, L Muul, R A Morgan, W F Anderson.
Abstract
In 1990, a clinical trial was started using retroviral-mediated transfer of the adenosine deaminase (ADA) gene into the T cells of two children with severe combined immunodeficiency (ADA- SCID). The number of blood T cells normalized as did many cellular and humoral immune responses. Gene treatment ended after 2 years, but integrated vector and ADA gene expression in T cells persisted. Although many components remain to be perfected, it is concluded here that gene therapy can be a safe and effective addition to treatment for some patients with this severe immunodeficiency disease.Entities:
Mesh：
Substances：
Year: 1995 PMID： 7570001 DOI： 10.1126/science.270.5235.475
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728